Immunitas Therapeutics
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- $68M
Investors
- 16
About Immunitas Therapeutics
Immunitas Therapeutics, Inc.Founded in 2019 and headquartered in Waltham, US, Immunitas Therapeutics is engaged in the development of therapeutics targeting cancer and autoimmune disorders.Immunitas Therapeutics specializes in developing innovative therapeutics aimed at treating cancer and autoimmune diseases. Its primary product, IMT-009, is an anti-CD161 monoclonal antibody currently in clinical trials for patients with refractory tumors, including those with MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer.Immunitas Therapeutics generates revenue primarily through clinical trials and the development of proprietary immuno-oncology and autoimmune therapies. The company collaborates with research institutions and pharmaceutical firms, facilitating agreements related to product development and commercialization.00 mn in August 2021, Immunitas Therapeutics intends to utilize these resources to advance its lead program, IMT-009, into clinical trials aimed at treating both solid tumors and hematological malignancies. The company is also exploring opportunities for product launches and market expansions, focusing on enhancing its presence in North America and Europe to address unmet medical needs in oncology and autoimmune sectors.
Who invested in Immunitas Therapeutics
16 investors across 2 rounds
See all investors in Immunitas Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunitas Therapeutics
Who invested in Immunitas Therapeutics?
Immunitas Therapeutics has 16 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunitas Therapeutics raised?
Immunitas Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunitas Therapeutics last raise money?
Immunitas Therapeutics's most recent round on record is a Series B, in Aug 2021.
What does Immunitas Therapeutics do?
Immunitas Therapeutics is a biotechnology company.
Where is Immunitas Therapeutics headquartered?
Immunitas Therapeutics is headquartered in Waltham, US.
Which VCs invest in companies like Immunitas Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immunitas Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immunitas Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.